论文部分内容阅读
联苯双酯为一新的治疗乙型病毒肝炎药物，本文对其致突变性进行了评价。当联苯双酯的浓度在１０，５０，１００和５００μｇ／皿，无论加或不加Ｓ＿９混合物对ＴＡ＿（９８）、ＴＡ＿（１００）、ＴＡ＿（１５３５）和ＴＡ＿（１５３７）菌株的回复突变作用均为阴性；当给昆明种小鼠剂量为３０００，１５００和７５０ｍｇ／ｋｇ的联苯双酯时，骨髓嗜多染细胞的微核率分别为３．３‰，３．３‰和１．７‰；当浓度为５００，２５０和１２５μｇ／ｍｌ对中国仓鼠肺细胞的染色体畸变率为３‰，２‰和２‰，上述结果表明，联苯双酯没有致突作用。
Bifendate is a new drug for the treatment of hepatitis B virus. In this paper, its mutagenicity was evaluated. When the concentration of bifendate was 10, 50, 100 and 500μg / dish, the mutagenicity of TA_ (98), TA_ (100), TA_ (1535) and TA_ (1537) strains with or without S_9 mixture Were all negative; micronuclei rates of myeloid polychromatic cells were 3.3 ‰, 3.3 ‰ and 1.7, respectively, when the doses of bifendate to Kunming mice were 3000, 1500 and 750 mg / kg ‰. The chromosome aberration rates of Chinese hamster lung cells were 3 ‰, 2 ‰ and 2 ‰ at concentrations of 500, 250 and 125 μg / ml, respectively. These results indicated that bifendate had no neurite outgrowth.